Zhongke New Life Snags ￥200M in Series A Funding Round

According to PEdaily.cn, Shanghai-based Zhongke New Life Biotechnology Co., Ltd. ("Zhongke New Life") recently announced that it has closed the Series A round of nearly 200 million yuan, led by Lucion Capital and Wuxi Finance Capital, with participation from Funway Capital and others. The proceeds from this round will mainly be used for the construction of the production center and supercomputing center of the company's mass spectrometry platform, the R&D of products in precision medicine, and the expansion of the domestic and foreign markets. Applied Protein Technology

Founded in 2004 by the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences (SIBS), Zhongke New Life is mainly engaged in the application of mass spectrometry technology. The company has established three platforms of scientific and technological services (protein/modification/metabolism research), biopharmaceutical characterization, and precision medicine. It is one of the first companies to participate in international liver and plasma projects. Zhongke New Life has obtained the CMA metrology certification, DUNS Registered and ISO 9001 quality certification.

Zhongke New Life has provided sample tests and project services for more than 1,000 pharmaceutical enterprises, 2,000 research institutes and hospitals at home and abroad.

Wuxi Finance Capital is a municipal financial investment platform established in November 2013 in response to the financial policy of Wuxi Municipal Government, engaged in comprehensive asset management, operational financial service and strategic investment.

Lucion Capital is an influential professional venture capital institute and the first listed venture capital company in China. The company mainly invests in advanced manufacturing, modern agriculture, marine economy and other advantageous fields in Shandong, China, and other emerging industries including information technology, energy conservation & environmental protection, new energy, new materials, biotechnology, and high-end equipment manufacturing.